Public Funding

Many new developments of Medipan GmbH are supported by public subsidies. The innovative performance of Medipan GmbH can thus be fully exploited and contributes to the growth of the company, especially in recent years.

ERDF projects:

Title of the project

Automated determination of 8-OHdG 

Grant budget period:  January 1, 2020 - June 30, 2022

Reactive oxygen species (ROS) are continuously produced in living cells of aerobic organisms as part of physiological processes, metabolic and other biochemical reactions. These endogenously produced ROS and oxygen-free radicals have important physiological functions, but due to their reactive nature can cause oxidative damage to lipids, proteins and RNA/DNA. Exogenous factors such as stress, nutrition, sport, UV radiation, tobacco smoke, asbestos and carcinogenic substances can also produce ROS under various conditions. Under normal physiological conditions, a balance is maintained in all aerobic organisms between endogenous oxidants and numerous enzymatic and non-enzymatic/low molecular weight antioxidants. If an imbalance occurs, oxidants cause extensive damage to DNA, which in turn leads to ageing, malignant tumours and other degenerative diseases. In all living cells, damaged DNA is repaired enzymatically so that it regains its normal function, while defective DNA leads to mutations (base substitution, deletions and strand fragmentation) that can lead to carcinogenesis. Although oxidative damage to DNA leads to a broad range of sometimes very specific reaction products (bases and sugar modifications, covalent crosslinks, single- and double-stranded breaks), the interest focused mainly on nucleobase modifications and especially on the abundant 8-oxo-2-deoxyguanosine lesion, which is formed in vivo and can be quantitatively measured in cells after hydrolysis of the DNA to component bases.

Our participation in the following projects is funded by the European Regional Development Fund and the State of Brandenburg.

 


Community project NeuroMiR:

Title of the project

NeuroMiR - Tracking dementia in the blood

Grant budget period: February 1, 2022 - December 31, 2025

In modern society, the incidence of neurodegenerative diseases such as Alzheimer's and Parkinson's is steadily increasing. Emerging symptoms range from memory and movement disorders to the inability to lead a self-determined life. These changes place extraordinary burdens on both the patients themselves and their relatives. Until now, a reliable diagnosis has only been detectable after the onset of the disease. Early diagnosis with various parameters play a very important role to detect the disease as early as possible and to be able to influence its course at an early stage.

Recent scientific discoveries show great potential in the new biomarker class microRNA, which shows characteristic changes in patients even before the first symptoms appear. In medicine, biomarkers are measurable parameters of biological processes that have prognostic or diagnostic significance. Therefore, they can be used as indicators for diseases.

The vision of the collaborative project NeuroMiR is the routine measurement of microRNAs in the blood of patients alongside conventional protein markers.

For this purpose, a small blood sample should be sufficient instead of a time-consuming and risky extraction from the bone marrow. The collaborative project led by medical scientist and entrepreneur Prof. Dr. Dirk Roggenbuck is developing a platform based on videoscan technology that detects both protein and nucleic acid biomarkers simultaneously and highly sensitively. The biomarkers are bound from patient blood by specific antibodies or capture probes coupled to micrometer-sized polymer particles (beads). Embedded in a novel hydrogel, near-infrared (NIR) signals are generated on the bead by enzymatic reaction and detected by a NIR fluorescence microscope. Subsequently the beads are further processed within the microfluidic chips to investigate multiple biomarkers simultaneously. The result is a highly sensitive bead-based multiparameter analysis that can be used for point-of-care diagnostics and is expandable to additional biomarkers in the future.

The regional focus of this cluster is in the Berlin/Brandenburg region including connections to Thuringia and Saxony. The Cluster partners include three research institutions: the Professorship of Immunotechnology at the University of Potsdam, the Brandenburg Technical University Cottbus-Senftenberg and the German Center for Neurodegenerative Diseases in Berlin, together with six small and medium-sized companies: GA Generic Assays GmbH, Medipan GmbH, Askion GmbH, BiFlow GmbH, PolyAn GmbH and new/era/mabs GmbH.

The project is one of 12 collaborative projects funded by the BMBF's RUBIN program for the promotion of regional small and medium-sized enterprises.

Source:  NeuroMiR


ERDF projects: 

Exhibitions and congresses

Our participation in the following congresses is funded by the European Regional Development Fund

and the State of Brandenburg.

 

2022

13. Int. Congress on Autoimmunity

Athen (GR)

10 - 16 June 2022

2021

Medlab Middle East 2021

Dubai (VAE)

21 - 24 June 2021

 

12. Int. Congress on Autoimmunity

Athen (GR)

28 May - 1 June 2021

2020

MEDICA Düsseldorf 2020

Düsseldorf

16 - 19 November 2020

 

Medlab Middle East 2020

Dubai (VAE)

3 - 6 February 2020

­


We thank all funding agencies for their confidence!